Subcutaneous (SC) Injection of CD101, a Novel Echinocandin: Efficacious, Well-Tolerated and Sustained Drug Exposures

V. Ong¹, T. Sandison¹, G. Hough¹, M. Schlosser¹, K. Bartzial¹, M. Peek², S.R. Lopez²
¹Cidara Therapeutics, San Diego, CA; ²TransPharm Preclinical Solutions, Jackson, MI

INTRODUCTION

CD101 is a novel echinocandin displaying exceptional stability, solubility, long-acting pharmacokinetics (PK) and robust antifungal efficacy in animal models.¹,² and is being developed for once-weekly intravenous (IV) administration for invasive fungal infections. CD101 was shown to have potent in vitro activity against reference strains of numerous Candida spp., Aspergillus spp., and other fungi with activity comparable to or superior to that of other echinocandins.³ Capitalizing on the stability and solubility of CD101, we postulate that the availability of an intermittent subcutaneous (SC) administration may further extend the utility of CD101 as an antifungal beyond that of other currently marketed echinocandins. Preclinical studies were conducted to evaluate the efficacy, safety and PK of CD101 by SC administration.

METHODS

Mouse Disseminated Infection Models. The efficacy of CD101 SC was studied in immunocompetent DBA/2 and neutropenic ICR mouse models of disseminated candidiasis. DBA/2 mice (5/gpr) were challenged with Candida albicans SC5314 (ATCC: MYA-2876, fluconazole-sensitive human clinical isolate shown to be pathogenic in mice) via IV injection (100 μL, 5 log CFU/mouse) and treated with CD101 SC (1, 3, and 10 mg/kg). Micafungin via IP administration was tested as a positive control at the same 3 doses. At 24 hours following challenge, kidneys were harvested and processed for CFU enumeration. CD101 SC (5 mg/kg) was also tested in the same disseminated Candidiasis model using neutropenic ICR mice (cyclophosphamide days -4 [150 mg/kg] and -1 [100 mg/kg]).

Monkey SC Tolerance/PK Study. One male and one female monkey were observed for up to 10 days following a single 30 mg/kg SC dose. In the same study, to determine the pharmacokinetics of CD101 following SC administration, whole blood samples were collected and the plasma was harvested at approximately 0.25, 0.5, 1, 2, 4, 8, 24, 36, and 48 hours, and 3, 4, 5, 7, and 10 days postdose. Plasma concentrations were then quantified by liquid chromatography with tandem mass spectrometric detection (LC-MS/MS).

RESULTS

In the DBA/2 mouse model, vehicle-treated mice showed mean log CFU of 3.8 at 2 hr increase to 6.1 at 24 hr. CD101 SC (1, 3, and 10 mg/kg) showed significant reduction in kidney CFU when compared to the vehicle control with complete CFU clearance at 3 or 10 mg/kg, and 4/5 animals in the 1 mg/kg group were completely cleared of CFU burden. A significant CFU reduction (4/5 animals showed complete clearance) was also observed in neutropenic ICR mice given a single SC dose of 5 mg/kg CD101.

CONCLUSIONS

CD101 as a single SC dose was efficacious, well tolerated and achieved sustained exposures with total AUC comparable to that of IV. CD101 SC could serve as a potential new agent and route of administration for intermittent outpatient echinocandin treatment and prophylaxis.

REFERENCES


ACKNOWLEDGMENTS

This study was funded by Cidara Therapeutics, Inc. T.S., and K.B. hold stock in Cidara Therapeutics. Editorial support was provided by Tressa Chung, RPh, CMP (TMC Medical Communications).